Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Treace Medical Concepts Reaffirms FY24 Revenue Guidance Of $201M - $211M, Est $205.405M

Author: Benzinga Newsdesk | August 06, 2024 06:06pm

The Company continues to expect Adjusted EBITDA to improve approximately 50% compared to full-year 2023.*

Posted In: TMCI